News and views, Straight from the Doc

Visit Straight From the Doc

Abbott's HUMIRA(R) (adalimumab) FDA-Approved For Moderate to Severe Chronic Plaque Psoriasis

Posted on January 21, 2008

The US FDA has recently approved the marketing of Abbott's HUMIRA(R) (adalimumab) as a treatment for adult patients with moderate to severe chronic plaque psoriasis.Plaque psoriasis is an autoimmune disease characterized by skin lesions that are sometimes painful and itchy.HUMIRA has been approved for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular...

Original article link


ankylosing spondylitis , arthritis , crohns disease , psoriatic arthritis , rheumatoid arthritis , skin